Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Morra

Showing results (81-90 of 143) with videos related to

Pageof 15
Sort By:
Applied Optics|July 28, 2016
Performance evaluation of hybrid DPSK-MPPM techniques in long-haul optical transmissionAbdulaziz E El-Fiqi, Ahmed E Morra, Salem F Hegazy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapyE Brusamolino, E Orlandi, E Morra, et al.
European Journal of Haematology|May 1, 1989
Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working FormulationE Morra, M Lazzarino, A Castello, et al.
Cancer|May 1, 1985
Clinicopathologic and immunologic characteristics of non-Hodgkin's lymphomas presenting in the orbit. A report of eight casesM Lazzarino, E Morra, R Rosso, et al.
British Journal of Haematology|June 1, 1989
Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosisM Lazzarino, A Vitale, E Morra, et al.
Cancer|November 26, 1999
Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromesF Ferrara, F Leoni, A Pinto, et al.
European Journal of Haematology|September 1, 1995
Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patientsA Ferrajoli, A M Liberati, P Caricchi, et al.
Leukemia Research|December 22, 2007
Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapyA Corso, S Mangiacavalli, L Barbarano, et al.
European Journal of Haematology|November 1, 1989
Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemiaM Lazzarino, E Morra, E P Alessandrino, et al.
Hematological Oncology|November 1, 1991
Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyureaM Lazzarino, E Morra, E Brusamolino, et al.
Pageof 15

Showing results (81-90 of 143) with videos related to

Sort By:
Pageof 15
Applied Optics|July 28, 2016
Performance evaluation of hybrid DPSK-MPPM techniques in long-haul optical transmissionAbdulaziz E El-Fiqi, Ahmed E Morra, Salem F Hegazy, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapyE Brusamolino, E Orlandi, E Morra, et al.
European Journal of Haematology|May 1, 1989
Bone marrow and blood involvement by non-Hodgkin's lymphoma: a study of clinicopathologic correlations and prognostic significance in relationship to the Working FormulationE Morra, M Lazzarino, A Castello, et al.
Cancer|May 1, 1985
Clinicopathologic and immunologic characteristics of non-Hodgkin's lymphomas presenting in the orbit. A report of eight casesM Lazzarino, E Morra, R Rosso, et al.
British Journal of Haematology|June 1, 1989
Interferon alpha-2b as treatment for Philadelphia-negative chronic myeloproliferative disorders with excessive thrombocytosisM Lazzarino, A Vitale, E Morra, et al.
Cancer|November 26, 1999
Fludarabine, cytarabine, and granulocyte-colony stimulating factor for the treatment of high risk myelodysplastic syndromesF Ferrara, F Leoni, A Pinto, et al.
European Journal of Haematology|September 1, 1995
Interferon-alpha plus low-dose cytosine arabinoside in advanced phase chronic myelogenous leukaemia patientsA Ferrajoli, A M Liberati, P Caricchi, et al.
Leukemia Research|December 22, 2007
Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapyA Corso, S Mangiacavalli, L Barbarano, et al.
European Journal of Haematology|November 1, 1989
Mitoxantrone and etoposide: an effective regimen for refractory or relapsed acute myelogenous leukemiaM Lazzarino, E Morra, E P Alessandrino, et al.
Hematological Oncology|November 1, 1991
Treatment of terminal-phase chronic myelogenous leukemia with intermediate-dose cytarabine and hydroxyureaM Lazzarino, E Morra, E Brusamolino, et al.
Pageof 15